Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent
View/ Open
Author
Sukhatme, Vidula
Bouche, Gauthier
Meheus, Lydie
Pantziarka, Pan
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.3332/ecancer.2015.568Metadata
Show full item recordCitation
Sukhatme, Vidula, Gauthier Bouche, Lydie Meheus, Vikas P Sukhatme, and Pan Pantziarka. 2015. “Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent.” ecancermedicalscience 9 (1): 568. doi:10.3332/ecancer.2015.568. http://dx.doi.org/10.3332/ecancer.2015.568.Abstract
Nitroglycerin (NTG), a drug that has been in clinical use for more than a century, has a range of actions which make it of particular interest in an oncological setting. It is generally accepted that the main mechanism of action of NTG is via the production of nitric oxide (NO), which improves cardiac oxygenation via multiple mechanisms including improved blood flow (vasodilation), decreased platelet aggregation, increased erythrocyte O2 release and decreased mitochondrial utilization of oxygen. Its vasoactive properties mean that it has the potential to exploit more fully the enhanced permeability and retention effect in delivering anti-cancer drugs to tumour tissues. Moreover NTG can reduce HIF-1α levels in hypoxic tumour tissues and this may have anti-angiogenic, pro-apoptotic and anti-efflux effects. Additionally NTG may enhance anti-tumour immunity. Pre-clinical and clinical data on these anti-cancer properties of NTG are summarised and discussed. While there is evidence of a positive action as a monotherapy in prostate cancer, there are mixed results in NSCLC where initially positive results have yet to be fully replicated. Based on the evidence presented, a case is made that further exploration of the clinical benefits that may accrue to cancer patients is warranted. Additionally, it is proposed that NTG may synergise with a number of other drugs, including other repurposed drugs, and these are discussed in the supplementary material appended to this paper.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583240/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:23473907
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)